HealthCare Global Enterprises Ltd
P&L
Quarterly Consolidated
vs Q4 FY25
HealthCare Global Enterprises Ltd Reports 417% Profit Growth in Q1FY26
01 Aug 2025 · 1 Aug 2025, 10:31 pm
Summary
HealthCare Global Enterprises Ltd (HCG) reported a 417% growth in profit after tax for the quarter ended June 30, 2025 (Q1FY26) compared to the same period last year. The revenue stood at Rs. 6,132 mn, a growth of 17% Y-o-Y. The adjusted EBITDA stood at Rs. 1,118 mn with 18.2% EBITDA margin for Q1FY26.
Key Highlights
- 1
Revenue stood at Rs. 6,132 mn a growth of 17% Y-o-Y
- 2
Adjusted EBITDA stood at Rs. 1,118 mn (20% Y-o-Y growth) with 18.2% EBITDA margin for Q1FY26
- 3
OPD Volumes grew by 17% compared to same period last year
- 4
LINAC capacity utilization on a like for like basis stood at 69% for Q1FY26 compared to 65% in Q1FY25
- 5
Overall ARPOB stood at Rs. 44,751 vs. Rs. 44,342 in Q1FY25, a growth of 0.9%
- 6
PAT for the quarter stood at Rs. 47.3 mn compared to Rs. 120.8 mn
Management Comments
Dr. B.S. Ajaikumar
Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd.
HCG continues to be on a strong growth trajectory, anchored by its leadership in cancer care, trusted brand, and commitment to clinical excellence. We remain focused on pioneering advanced technologies in India, including Cyclotron, Adaptive RT, CyberKnife, and Al-driven systems, while expanding capabilities in genomics and proteomics. Our integrated, multidisciplinary approach ensures that patients receive the right treatment the first time across our growing network.
Dr. Manish Mattoo
CEO HealthCare Global Enterprises Ltd.
HCG has long stood as a beacon of excellence in cancer care, consistently setting new benchmarks in clinical innovation and outcomes. At the core of this success is its world-class team of oncologists, surgeons, and specialists, supported by a deeply ingrained culture of multidisciplinary collaboration and cutting-edge technology. With a strong pan-India presence built over more than two decades, HCG ensures that high-quality and advanced cancer care is accessible to patients across the country.
Informational and educational content only. Not investment advice.